Al-Maskari Fatma, El-Sadig Mohammed, Obineche Enyioma
Department of Community Medicine, Faculty of Medicine & Health Sciences, Al-Ain City, United Arab Emirates University, PO Box: 17666, UAE.
BMC Nephrol. 2008 Jan 29;9:1. doi: 10.1186/1471-2369-9-1.
Microalbuminuria (MA) represents the earliest clinical evidence of diabetic nephropathy and is a predictor of increased cardiovascular morbidity and mortality. The aim of this study was to determine the prevalence of MA among diabetic patients in the Al-Ain district of the United Arab Emirates (UAE).
The study was part of a general cross-sectional survey carried out to assess the prevalence of diabetes mellitus (DM) complications in Al-Ain district, UAE and was the first to assess the prevalence of MA among diabetic patients. A sample of 513 diabetic patients with a mean age of 53 years (SD: +/- 13) was randomly selected during 2003/2004. All patients completed an interviewer-administered questionnaire and underwent medical assessment. First morning urine collections were obtained and were tested for clinical proteinuria using urine dipsticks and for MA using the single Micral-Test II strips.
MA was found in 61% (95% CI: 56.7-65.7) of the sample and the rate was significantly higher among males, positively related to body mass index (BMI), type 2 DM and presence of other DM complications such as diabetic retinopathy and neuropathy. Of the total sample population, 12.5% (95% CI: 8.1-14.1) had clinical proteinuria.
The prevalence rate of MA was considerably high ( 61%) among diabetic patients in the UAE. Therefore, regular screening for MA is recommended for all diabetic patients, as early treatment is critical for reducing cardiovascular risks and slowing the progression to late stages of diabetic nephropathy (overt proteinuria and end-stage renal disease).
微量白蛋白尿(MA)是糖尿病肾病最早的临床证据,也是心血管疾病发病率和死亡率增加的预测指标。本研究的目的是确定阿拉伯联合酋长国(UAE)艾因地区糖尿病患者中MA的患病率。
该研究是为评估阿联酋艾因地区糖尿病(DM)并发症患病率而开展的一项综合性横断面调查的一部分,也是首次评估糖尿病患者中MA的患病率。2003年/2004年期间,随机选取了513名平均年龄为53岁(标准差:±13)的糖尿病患者作为样本。所有患者均完成了一份由调查员填写的问卷,并接受了医学评估。收集了患者的首次晨尿,使用尿试纸检测临床蛋白尿,使用单一的Micral-Test II试纸检测MA。
样本中61%(95%置信区间:56.7-65.7)的患者存在MA,男性患病率显著更高,并与体重指数(BMI)、2型糖尿病以及糖尿病视网膜病变和神经病变等其他糖尿病并发症的存在呈正相关。在全部样本人群中,12.5%(95%置信区间:8.1-14.1)的患者存在临床蛋白尿。
阿联酋糖尿病患者中MA的患病率相当高(61%)。因此,建议对所有糖尿病患者进行MA的定期筛查,因为早期治疗对于降低心血管风险以及减缓糖尿病肾病进展至晚期(显性蛋白尿和终末期肾病)至关重要。